Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

NCT06532058 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)

Interventions

DRUG: QHRD107 capsule，Venclexta and Azacitidine

Sponsor

Changzhou Qianhong Bio-pharma Co., Ltd.